News | November 13, 2013

InspireMD's MGuard Stent Shows Lower Mortality Rate in STEMI Patients at 12 Months Compared to Control Group

clinical trial study stents cath lab mguard inspiremd
November 13, 2013 — InspireMD Inc., a developer of embolic protection stents, announced 12-month results from the MGuard for Acute ST Elevation Reperfusion (MASTER) trial demonstrating that the MGuard outperformed bare metal and drug-eluting stents in all-cause mortality in ST segment elevation myocardial infarction (STEMI) patients. Results from the trial were presented at the Transcatheter Cardiovascular Therapeutics Conference (TCT 2013) in San Francisco.
 
The MGuard utilizes the InspireMD's proprietary MicroNet technology, which is a circular knitted mesh that wraps around the stent to protect patients from plaque debris flowing downstream upon deployment. This technology allows the MGuard to specifically address the unmet need for ST segment elevation myocardial infarction (STEMI) patients and save the life of those who suffer from heart attacks.
 
The MASTER trial achieved its primary endpoint (p = 0.008) in complete ST-segment resolution at 60-90 minutes post-procedure. Secondary endpoint clinical outcomes continued to show a lower mortality rate with the MGuard EPS (embolic protection stent) compared to the control (1 percent versus 3.3 percent, p = 0.092) at 12 months. These findings are in line with the previously announced six-month follow-up results showing that all-cause mortality with MGuard EPS was lower than bare metal and drug-eluting stents used as a control (0.5 percent versus 2.8 percent, p = 0.056). Additional 12-month results are available on InspireMD’s website.
 
"This data further supports the evidence that positive acute results at the time the patient is treated are associated with improved outcomes at 12 months,” said Alan Milinazzo, president and CEO, InspireMD. “Additionally and importantly, the subset data we released on treatment time from symptom onset to reperfusion revealed that MGuard may increase the therapeutic window for physicians treating STEMI patients. This could be a very important factor when physicians assess clinical treatment options for their patients."
 
"It is very reassuring to see that the 12-month follow up data is consistent with the acute results presented at TCT last year, especially the data that shows the mortality benefit trend of using this unique technology," said Dariusz Dudek, physician-in-chief, 2nd Department of Clinical Cardiology and Cardiovascular Interventions, University Hospital in Krakow. "These positive results should give clinicians the confidence to use MGuard technology as a first line of defense against distal embolization for their STEMI patients."
 
The MASTER trial enrolled a total of 433 patients with STEMI presenting within 12 hours of symptom onset undergoing percutaneous coronary intervention (PCI) were randomized at 50 sites in nine countries to the MGuard EPS (n = 217) or commercially available bare metal or drug-eluting stents (n = 216).
 
MGuard EPS is CE mark-approved. It is not approved for sale in the United States at this time.
 
For more information: www.inspire-md.com

Related Content

New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
Overlay Init